Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$5.96 +2.4%	$9.14	$4.01 ▼ $11.99	$116.94M	N/A	55,946 shs	966,466 shs
CRBU Caribou Biosciences	$1.26 -6.7%	$1.03	$0.66 ▼ $3.00	$117.18M	2.44	1.33 million shs	12.13 million shs
MDCX Medicus Pharma	$2.90 -6.5%	$4.13	$1.80 ▼ $8.94	$39.35M	N/A	294,388 shs	324,346 shs
NMRA Neumora Therapeutics	$0.76 -5.3%	$0.76	$0.61 ▼ $17.19	$122.43M	2.74	1.52 million shs	10.84 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	0.00%	-20.21%	-47.54%	-11.96%	+595,999,900.00%
CRBU Caribou Biosciences	0.00%	-5.97%	+17.21%	+37.99%	-23.17%
MDCX Medicus Pharma	0.00%	+16.47%	+18.37%	-22.04%	+289,999,900.00%
NMRA Neumora Therapeutics	0.00%	-3.67%	+6.71%	-24.31%	-92.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	2.0068 of 5 stars	3.5	0.0	2.6	1.7	0.0
CRBU Caribou Biosciences	2.0568 of 5 stars	3.5	1.0	2.2	1.7	0.6
MDCX Medicus Pharma	1.9401 of 5 stars	3.8	0.0	2.5	0.8	0.0
NMRA Neumora Therapeutics	2.3495 of 5 stars	3.1	1.0	2.2	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	243.96% Upside
CRBU Caribou Biosciences	3.00	Buy	$8.50	574.60% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	710.34% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,126.81% Upside

Current Analyst Ratings Breakdown

Latest MDCX, ACTU, CRBU, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/13/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/12/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $27.00
5/8/2025	MDCX Medicus Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
4/28/2025	CRBU Caribou Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $3.00
4/28/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
CRBU Caribou Biosciences	$9.99M	11.73	N/A	N/A	$2.79 per share	0.45
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.29 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	N/A	-339.73%	N/A
CRBU Caribou Biosciences	-$149.10M	-$1.62	N/A	N/A	N/A	-1,490.84%	-55.70%	-45.35%	8/5/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.16	N/A	N/A	N/A	N/A	-380.03%	-224.22%	8/11/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/5/2025 (Estimated)

Latest MDCX, ACTU, CRBU, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ACTU Actuate Therapeutics	-$0.26	-$0.32	-$0.06	-$0.32	N/A	N/A
5/12/2025	Q1 2025	MDCX Medicus Pharma	-$0.23	-$0.42	-$0.19	-$0.42	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
5/8/2025	Q1 2025	CRBU Caribou Biosciences	-$0.43	-$0.43	N/A	-$0.43	$1.48 million	$2.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.46	0.46
CRBU Caribou Biosciences	N/A	7.63	7.63
MDCX Medicus Pharma	N/A	1.53	1.53
NMRA Neumora Therapeutics	N/A	8.98	8.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
CRBU Caribou Biosciences	77.51%
MDCX Medicus Pharma	N/A
NMRA Neumora Therapeutics	47.65%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
CRBU Caribou Biosciences	9.50%
MDCX Medicus Pharma	N/A
NMRA Neumora Therapeutics	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	19.62 million	6.02 million	N/A
CRBU Caribou Biosciences	100	93.00 million	84.17 million	Optionable
MDCX Medicus Pharma	N/A	13.57 million	N/A	N/A
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable

MDCX, ACTU, CRBU, and NMRA Headlines

Recent News About These Companies

Lunate Capital Ltd Acquires Shares of 2,124,143 Neumora Therapeutics, Inc. (NASDAQ:NMRA)

June 29 at 7:38 AM | marketbeat.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Average PT from Analysts

June 29 at 2:17 AM | americanbankingnews.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Analysts

June 26, 2025 | marketbeat.com

Neumora Therapeutics Inc News (NMRA) - Investing.com

June 24, 2025 | investing.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by Analysts

June 1, 2025 | marketbeat.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 27, 2025 | globenewswire.com

Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development

May 24, 2025 | uk.investing.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 14, 2025 | prnewswire.com

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finanznachrichten.de

Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...

May 13, 2025 | finance.yahoo.com

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?

May 11, 2025 | finance.yahoo.com

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

April 28, 2025 | globenewswire.com

Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Up 10.34%

April 23, 2025 | aaii.comA

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

April 16, 2025 | investing.com

Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating

April 9, 2025 | tipranks.com

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bronstein, Gewirtz & Grossman, LLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

April 8, 2025 | accessnewswire.comA

Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline

April 7, 2025 | accessnewswire.comA

NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

April 7, 2025 | globenewswire.com

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.

April 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Micron Joins Latest $200 Billion United States Investment
By Gabriel Osorio-Mazilli | June 16, 2025
View Micron Joins Latest $200 Billion United States Investment
Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw
By Leo Miller | June 4, 2025
View Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
By Sam Quirke | June 11, 2025
View Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal

MDCX, ACTU, CRBU, and NMRA Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$5.96 +0.14 (+2.41%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.01 -1.95 (-32.72%)

As of 04:00 AM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Caribou Biosciences NASDAQ:CRBU

$1.26 -0.09 (-6.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.21 -0.05 (-3.97%)

As of 04:03 AM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Medicus Pharma NASDAQ:MDCX

$2.90 -0.20 (-6.45%)

As of 06/27/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Neumora Therapeutics NASDAQ:NMRA

$0.76 -0.04 (-5.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.78 +0.03 (+3.71%)

As of 04:00 AM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time